These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10428367)

  • 1. Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivity.
    Boyd SA; Mantei RA; Tasker AS; Liu G; Sorensen BK; Henry KJ; von Geldern TW; Winn M; Wu-Wong JR; Chiou WJ; Dixon DB; Hutchins CW; Marsh KC; Nguyen B; Opgenorth TJ
    Bioorg Med Chem; 1999 Jun; 7(6):991-1002. PubMed ID: 10428367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
    Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.
    Jae HS; Winn M; von Geldern TW; Sorensen BK; Chiou WJ; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 2001 Nov; 44(23):3978-84. PubMed ID: 11689084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
    Wu-Wong JR; Dixon DB; Chiou WJ; Dayton BD; Novosad EI; Adler AL; Wessale JL; Calzadilla SV; Hernandez L; Marsh KC; Liu G; Szczepankiewicz B; von Geldern TW; Opgenorth TJ
    Eur J Pharmacol; 1999 Feb; 366(2-3):189-201. PubMed ID: 10082200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
    Winn M; von Geldern TW; Opgenorth TJ; Jae HS; Tasker AS; Boyd SA; Kester JA; Mantei RA; Bal R; Sorensen BK; Wu-Wong JR; Chiou WJ; Dixon DB; Novosad EI; Hernandez L; Marsh KC
    J Med Chem; 1996 Mar; 39(5):1039-48. PubMed ID: 8676339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine.
    Burke SE; Nelson RA; Lubbers NL; Ford TT; Fu KI; Padley RJ; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):838-44. PubMed ID: 10836715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
    Sudoh K; Yuyama H; Noguchi Y; Fujimori A; Ukai M; Ohtake A; Sato S; Sasamata M; Miyata K
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S390-3. PubMed ID: 15838329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
    Liu G; Kozmina NS; Winn M; von Geldern TW; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 1999 Sep; 42(18):3679-89. PubMed ID: 10479299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of diminishing albumin binding to some Endothelin receptor antagonists.
    Szczepankiewicz BG; Bal RB; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Opgenorth TJ; Hoffman DJ; Borre AJ; Marsh KC; Nguyen BN
    Life Sci; 1998; 63(21):1905-12. PubMed ID: 9825768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain.
    Jarvis MF; Wessale JL; Zhu CZ; Lynch JJ; Dayton BD; Calzadilla SV; Padley RJ; Opgenorth TJ; Kowaluk EA
    Eur J Pharmacol; 2000 Jan; 388(1):29-35. PubMed ID: 10657544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
    Thakkar SG; Choueiri TK; Garcia JA
    Curr Oncol Rep; 2006 Mar; 8(2):108-13. PubMed ID: 16507220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21: development of endothelin-B receptor selective antagonists.
    Cody WL; He JX; DePue PL; Waite LA; Leonard DM; Sefler AM; Kaltenbronn JS; Haleen SJ; Walker DM; Flynn MA
    J Med Chem; 1995 Jul; 38(15):2809-19. PubMed ID: 7636842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of a novel class of endothelin-A receptor antagonists and discovery of potent and selective receptor antagonist, 2-(benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2H-chromene-3-carboxylic acid (S-1255). 1. Study on structure-activity relationships and basic structure crucial for ET(A) antagonism.
    Ishizuka N; Matsumura K; Sakai K; Fujimoto M; Mihara S; Yamamori T
    J Med Chem; 2002 May; 45(10):2041-55. PubMed ID: 11985472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents.
    Ergul A
    Pharmacotherapy; 2002 Jan; 22(1):54-65. PubMed ID: 11794430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of selective and non-selective endothelin receptor blockade on ET-1-induced pressor response in the hamster.
    Honoré JC; Fecteau MH; Wessale JL; D'Orléans-Juste P
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S68-71. PubMed ID: 15838362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level.
    Opgenorth TJ; Wessale JL; Dixon DB; Adler AL; Calzadilla SV; Padley RJ; Wu-Wong JR
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S292-6. PubMed ID: 11078402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.
    von Geldern TW; Tasker AS; Sorensen BK; Winn M; Szczepankiewicz BG; Dixon DB; Chiou WJ; Wang L; Wessale JL; Adler A; Marsh KC; Nguyen B; Opgenorth TJ
    J Med Chem; 1999 Sep; 42(18):3668-78. PubMed ID: 10479298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
    Li JS; Turgeon A; Schiffrin EL
    Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.
    Wessale JL; Adler AL; Novosad EI; Calzadilla SV; Dayton BD; Marsh KC; Winn M; Jae HS; von Geldern TW; Opgenorth TJ; Wu-Wong JR
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():112S-117S. PubMed ID: 12193067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.
    Yuyama H; Noguchi Y; Fujimori A; Ukai M; Fujiyasu N; Ohtake A; Sato S; Sudoh K; Sasamata M; Miyata K
    Eur J Pharmacol; 2004 Sep; 498(1-3):171-7. PubMed ID: 15363992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.